Bradley C. Wright explains that Allergan’s transfer of patent rights to chronic dry eye medication Restasis to the Saint Regis Mohawk Tribe in upstate New York could be seen as “highly suspicious” by the Patent Trial and Appeal Board in Bloomberg Technology.
In the article, “A Native American Tribe, a Drugmaker and an Unusual Patent Plan,” Mr. Wright says the PTAB will take a close look at Allergan’s agreement with the tribe and may decide that the company retains enough control over the patents that the transfer is a “sham transfer of assets.”
Click here to read the article.
The article also appeared in The Seattle Times.
Posted: September 11, 2017
